A Curated Platform of Equity & Options Market Intelligence
Select Page

BYSI

Search by
TICKER SYMBOL

BeyondSpring Inc

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

2.09

0.03

(1.456%)

Volume:

46,767

52 week range:

0.6534 - 4

Market Cap:

81.351M

Company Description:

beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers